Hypofractionated Stereotactic Radiation Therapy in Treating Younger Patients with Metastatic Sarcomas of Bony Sites

Inclusion Criteria

• Patients must have histologically or cytologically confirmed non-rhabdomyosarcoma of soft tissue or bone at any site
• Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >= 20 mm with conventional techniques or as >= 10 mm with spiral CT scan within 4 weeks of treatment start
• Greatest tumor dimension of all sites must be =< 5.0 cm or < 250 cm^3
• There is at least 1 metastatic site at one or more of the following sites: spine or non-spine bone and at maximum 5 sites can be treated on protocol
• Surgically unresectable site as determined by tumor board or surgeon or patients who decline surgery
• Life expectancy of at least 9 months
• Lansky performance status >= 50
• Ability to understand and the willingness to sign a written informed consent document and if a minor, have a guardian who meets the above criteria

Exclusion Criteria

• Patients who have had chemotherapy or radiotherapy within 2 weeks prior to starting radiation treatment
• Patients who have had any prior radiotherapy to the treatment site(s)
• A patient may not participate in a concurrent treatment protocol; all patients will be eligible to receive chemotherapy alone, systemic therapeutic agents, or conventional chemo-radiotherapy at the time of clinical or radiographic disease progression or at 2 weeks following completion of SBRT
• Pregnant women are excluded from this study
• Refusal to take a pregnancy test prior to treatment if the patient is a woman with child bearing potential
• Patients with a rhabdomyosarcoma will be excluded